ライフサイエンスコーパス: glucuronoxylomannan

1 ted with higher serum titers of cryptococcal glucuronoxylomannan.

2 in building the main capsule polysaccharide, glucuronoxylomannan.

3 mAb 2H1 binds C. neoformans glucuronoxylomannan.

4 or the major type-specific capsular antigen, glucuronoxylomannan.

5 survival, reducing CFU, and reducing tissue glucuronoxylomannan Ag. mAb administration was associate

6 tococcus neoformans capsular polysaccharides glucuronoxylomannan and galactoxylomannan (GalXM) elicit

7 de of two xylose-containing polysaccharides, glucuronoxylomannan and galactoxylomannan.

8 Monoclonal antibodies to the capsular glucuronoxylomannan can modulate the infection in mice,

9 efficacy of mAbs to Cryptococcus neoformans glucuronoxylomannan depends on Ab isotype.

10 the MAb was not cross-reactive with purified glucuronoxylomannan derived from either serotypes A or D

11 1, one of a large family of mAbs against the glucuronoxylomannan fraction (GXM), is highly protective

12 n V region usage for Cryptococcus neoformans glucuronoxylomannan, glucuronoxylomannan peptide mimetic

13 sis of the two main capsule polysaccharides, glucuronoxylomannan (GXM) and galactoxylomannan (GalXM),

14 l for virulence and is composed primarily of glucuronoxylomannan (GXM) and galactoxylomannan (GalXM).

15 eactive with the cryptococcal polysaccharide glucuronoxylomannan (GXM) are present in sera from both

16 ine monoclonal antibodies (MAbs) against the glucuronoxylomannan (GXM) component of the C. neoformans

17 ith a glycoconjugate vaccine composed of the glucuronoxylomannan (GXM) component of the cryptococcal

18 ith a glycoconjugate vaccine composed of the glucuronoxylomannan (GXM) component of the cryptococcal

19 pertoire of human antibodies to cryptococcal glucuronoxylomannan (GXM) elicited by the investigationa

20 or (PAF) content in mice given C. neoformans glucuronoxylomannan (GXM) followed by specific Ab of IgG

21 o biological function of human antibodies to glucuronoxylomannan (GXM) from individuals immunized wit

22 ptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been rigorously investiga

23 ptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been shown to be protecti

24 to the C. neoformans capsular polysaccharide glucuronoxylomannan (GXM) have demonstrated that patient

25 response to Cryptococcus neoformans capsular glucuronoxylomannan (GXM) in BALB/c mice frequently expr

26 antibodies (Abs) to Cryptococcus neoformans glucuronoxylomannan (GXM) is dependent on Ab fine specif

27 Cryptococcus neoformans capsular glucuronoxylomannan (GXM) is shed during cryptococcosis

28 Most mAbs to the capsular polysaccharide glucuronoxylomannan (GXM) of Cryptococcus neoformans are

29 Specifically, the glucuronoxylomannan (GXM) of the WR polysaccharide diffe

30 IgA to the Cryptococcus neoformans capsular glucuronoxylomannan (GXM) promote complement-independent

31 epitope in Cryptococcus neoformans capsular glucuronoxylomannan (GXM) that can elicit protective ant

32 l constituents of native and de-O-acetylated glucuronoxylomannan (GXM) was determined by one-dimensio

33 Significantly less glucuronoxylomannan (GXM) was released by C. neoformans

34 ypes of cryptococcal capsular polysaccharide glucuronoxylomannan (GXM) was studied, followed by an as

35 Cryptococcal glucuronoxylomannan (GXM), but not galactoxylomannan or

36 or the major capsular polysaccharide, termed glucuronoxylomannan (GXM), can markedly suppress the abi

37 mAbs that recognize two epitopes of capsular glucuronoxylomannan (GXM), defined by the IgG1 mAbs 2H1

38 with cryptococcal capsular polysaccharide, a glucuronoxylomannan (GXM), exhibit increased survival ti

39 of CneF and its individual components, i.e., glucuronoxylomannan (GXM), galactoxylomannan (GalXM), an

40 rmine if cryptococcal polysaccharides, i.e., glucuronoxylomannan (GXM), galactoxylomannan, and mannop

41 ptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM), in mice that produce human an

42 r polysaccharide of Cryptococcus neoformans, glucuronoxylomannan (GXM), is recognized by Toll-like re

43 immunoglobulin M (IgM) and IgG responses to glucuronoxylomannan (GXM), lack of IgE regulation during

44 2H1, which binds to Cryptococcus neoformans glucuronoxylomannan (GXM), on pulmonary infection in imm

45 of the cryptococcal capsular polysaccharide glucuronoxylomannan (GXM), the key C. neoformans virulen

46 Monoclonal antibodies (MAbs) reactive with glucuronoxylomannan (GXM), the major capsular polysaccha

47 the host response to Cryptococcus neoformans glucuronoxylomannan (GXM), the major capsular polysaccha

48 urine macrophages treated with extracellular glucuronoxylomannan (GXM), the major Cn capsular polysac

49 Glucuronoxylomannan (GXM), the major component of the ca

50 ed that the 18B7 monoclonal antibody against glucuronoxylomannan (GXM), the major component of the Cr

51 CPS or its major component, glucuronoxylomannan (GXM), was administered to mice, and

52 city differences for Cryptococcus neoformans glucuronoxylomannan (GXM).

53 charide capsule whose primary constituent is glucuronoxylomannan (GXM).

54 levels of the major capsular polysaccharide, glucuronoxylomannan (GXM).

55 olysaccharide capsule comprised primarily of glucuronoxylomannan (GXM).

56 bodies (MAbs) to the capsular polysaccharide glucuronoxylomannan (GXM).

57 Cryptococcus neoformans glucuronoxylomannans (GXM) are capsular polysaccharides

58 Purified capsular polysaccharide (glucuronoxylomannan [GXM]) also stimulated the PC to sec

59 ropriate for a role in the synthesis of this glucuronoxylomannan is active in cryptococcal membranes.

60 Cryptococcus neoformans glucuronoxylomannan, glucuronoxylomannan peptide mimetics, and anti-Id mAbs.

61 Immunostaining for glucuronoxylomannan showed isolated cryptococci inside t

62 t have specificity appropriate for a role in glucuronoxylomannan synthesis, it may participate in pro

63 cryptococcal capsular polysaccharide vaccine glucuronoxylomannan-tetanus toxoid (GXM-TT) have been sh

64 These results indicate that glucuronoxylomannan, the major cryptococcal capsule poly

65 sion of antibodies to C. neoformans capsular glucuronoxylomannan were analyzed by ELISA.

66 saccharide capsule composed predominantly of glucuronoxylomannan, which constitutes approximately 90%